Dabigatran vs Rivaroxaban for Nonvalvular Atrial Fibrillation

This cohort study compares risks of thromboembolic stroke, intracranial hemorrhage, major extracranial bleeding, and mortality in Medicare beneficiaries with nonvalvular atrial fibrillation who initiated dabigatran or rivaroxaban therapy for stroke prevention.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research